Patient relevance and clinical translation are in the DNA of all the platforms developed by Mestastop Solutions. As the platforms are optimised and trained using patient data, thereby identifying key targets or molecules that can delay metastasis, the probability of failure in clinical trials is significantly lower. The advantage of using clinical samples to finalise the algorithm and the platforms ensures improvement over time as more patient data come in.
Patient primary tumours from clinically non-metastatic samples, irrespective of node status, are purified and cultured in 2D and 3D forms for various cell-based functional phenotypic assays. Mestastop Solutions is also developing high-throughput screening of patient samples in 3D format for identifying the best treatment options to accelerate discovery and clinical decision-making.
All clinical samples are tumour-review board approved and patient-consented along with Institutional Ethics Committee clearance. Following grant of all necessary approvals, the samples undergo detailed analysis, from mechanobiology to metabolic profiling.